2.1.1 Somatic cell therapies rely on isolation of some specific type of mature, differentiated cells from a patient, after which they are expanded and/or genetically modified in vitro. The classic example of autologous somatic cells used in therapeutics are the CAR-T therapeutics. These therapies rely on isolation of T cells from a patient, after which the T cells are genetically modified, expanded, and then injected back into the patient. Such therapies have been highly effective for engineering T cells of oncology patients to properly recognize specific tumor-associated antigens (TAA) and mount an effective immune response to the cancer.[67]
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.
2.2.1 The ultimate stem cell is a fertilized egg (classified as totipotent), and human embryonic tissue has been demonstrated to retain the ability to differentiate into many types of cells (pluripotent). Use of human embryonic stem cells (ESCs), however, encounters a host of ethical, political, and regulatory issues, so these cells are not often used in the development of therapeutics, although they have been critical to our understanding of stem cells. Adult multipotent stem cells that retain the ability to differentiate into several types of cells within the same class have also been successfully isolated from cord blood, and eight cord blood–based therapies have been approved, all of them for treatment of hematopoietic stem cell replacements.
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.
2.3.1 At the end of 2023, the Alliance for Regenerative Medicine (ARM) reported (from GlobalData) 2,120 clinical trials for advanced therapies underway around the world — a decrease of 4% from 2,220 trials in 2022. The global distribution of clinical trials around the world retained a similar pattern as in 2023, with 45% in North America, 35% in Asia–Pacific, and 20% in Europe (Figure 2). The trials are being sponsored by 2,526 cell and gene therapy developers.[3]
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.